Effects of a Province-wide Triaging System for TIA: The ASPIRE Intervention.

Autor:	Jeerakathil TJ; From the Department of Medicine (Neurology) (T.J.J., A.S.), and Division of General Internal Medicine (S.R.M., N.D.), University of Alberta (S.F), Edmonton; Alberta Health Services, Edmonton (T.J.J., A.S., D.G.) and Alberta Health Services, Calgary (C.E.); Department of Medicine (Neurology) (A.Y.X.Y.), University of Toronto, Ontario, Canada; Department of Neurosciences (P.M.C.C.), Monash University, Melbourne, Australia; Department of Clinical Neurosciences (A.M.D., T.J.W., M.D.H., S.B.C.), University of Calgary, Alberta, Canada; Neurology (K.B.), Prince of Wales Clinical School, University of New South Wales, Sydney, Australia. thomasj@ualberta.ca., Yu AYX; From the Department of Medicine (Neurology) (T.J.J., A.S.), and Division of General Internal Medicine (S.R.M., N.D.), University of Alberta (S.F), Edmonton; Alberta Health Services, Edmonton (T.J.J., A.S., D.G.) and Alberta Health Services, Calgary (C.E.); Department of Medicine (Neurology) (A.Y.X.Y.), University of Toronto, Ontario, Canada; Department of Neurosciences (P.M.C.C.), Monash University, Melbourne, Australia; Department of Clinical Neurosciences (A.M.D., T.J.W., M.D.H., S.B.C.), University of Calgary, Alberta, Canada; Neurology (K.B.), Prince of Wales Clinical School, University of New South Wales, Sydney, Australia., Choi PMC; From the Department of Medicine (Neurology) (T.J.J., A.S.), and Division of General Internal Medicine (S.R.M., N.D.), University of Alberta (S.F), Edmonton; Alberta Health Services, Edmonton (T.J.J., A.S., D.G.) and Alberta Health Services, Calgary (C.E.); Department of Medicine (Neurology) (A.Y.X.Y.), University of Toronto, Ontario, Canada; Department of Neurosciences (P.M.C.C.), Monash University, Melbourne, Australia; Department of Clinical Neurosciences (A.M.D., T.J.W., M.D.H., S.B.C.), University of Calgary, Alberta, Canada; Neurology (K.B.), Prince of Wales Clinical School, University of New South Wales, Sydney, Australia., Fang S; From the Department of Medicine (Neurology) (T.J.J., A.S.), and Division of General Internal Medicine (S.R.M., N.D.), University of Alberta (S.F), Edmonton; Alberta Health Services, Edmonton (T.J.J., A.S., D.G.) and Alberta Health Services, Calgary (C.E.); Department of Medicine (Neurology) (A.Y.X.Y.), University of Toronto, Ontario, Canada; Department of Neurosciences (P.M.C.C.), Monash University, Melbourne, Australia; Department of Clinical Neurosciences (A.M.D., T.J.W., M.D.H., S.B.C.), University of Calgary, Alberta, Canada; Neurology (K.B.), Prince of Wales Clinical School, University of New South Wales, Sydney, Australia., Shuaib A; From the Department of Medicine (Neurology) (T.J.J., A.S.), and Division of General Internal Medicine (S.R.M., N.D.), University of Alberta (S.F), Edmonton; Alberta Health Services, Edmonton (T.J.J., A.S., D.G.) and Alberta Health Services, Calgary (C.E.); Department of Medicine (Neurology) (A.Y.X.Y.), University of Toronto, Ontario, Canada; Department of Neurosciences (P.M.C.C.), Monash University, Melbourne, Australia; Department of Clinical Neurosciences (A.M.D., T.J.W., M.D.H., S.B.C.), University of Calgary, Alberta, Canada; Neurology (K.B.), Prince of Wales Clinical School, University of New South Wales, Sydney, Australia., Majumdar SR; From the Department of Medicine (Neurology) (T.J.J., A.S.), and Division of General Internal Medicine (S.R.M., N.D.), University of Alberta (S.F), Edmonton; Alberta Health Services, Edmonton (T.J.J., A.S., D.G.) and Alberta Health Services, Calgary (C.E.); Department of Medicine (Neurology) (A.Y.X.Y.), University of Toronto, Ontario, Canada; Department of Neurosciences (P.M.C.C.), Monash University, Melbourne, Australia; Department of Clinical Neurosciences (A.M.D., T.J.W., M.D.H., S.B.C.), University of Calgary, Alberta, Canada; Neurology (K.B.), Prince of Wales Clinical School, University of New South Wales, Sydney, Australia., Demchuk AM; From the Department of Medicine (Neurology) (T.J.J., A.S.), and Division of General Internal Medicine (S.R.M., N.D.), University of Alberta (S.F), Edmonton; Alberta Health Services, Edmonton (T.J.J., A.S., D.G.) and Alberta Health Services, Calgary (C.E.); Department of Medicine (Neurology) (A.Y.X.Y.), University of Toronto, Ontario, Canada; Department of Neurosciences (P.M.C.C.), Monash University, Melbourne, Australia; Department of Clinical Neurosciences (A.M.D., T.J.W., M.D.H., S.B.C.), University of Calgary, Alberta, Canada; Neurology (K.B.), Prince of Wales Clinical School, University of New South Wales, Sydney, Australia., Butcher K; From the Department of Medicine (Neurology) (T.J.J., A.S.), and Division of General Internal Medicine (S.R.M., N.D.), University of Alberta (S.F), Edmonton; Alberta Health Services, Edmonton (T.J.J., A.S., D.G.) and Alberta Health Services, Calgary (C.E.); Department of Medicine (Neurology) (A.Y.X.Y.), University of Toronto, Ontario, Canada; Department of Neurosciences (P.M.C.C.), Monash University, Melbourne, Australia; Department of Clinical Neurosciences (A.M.D., T.J.W., M.D.H., S.B.C.), University of Calgary, Alberta, Canada; Neurology (K.B.), Prince of Wales Clinical School, University of New South Wales, Sydney, Australia., Watson TJ; From the Department of Medicine (Neurology) (T.J.J., A.S.), and Division of General Internal Medicine (S.R.M., N.D.), University of Alberta (S.F), Edmonton; Alberta Health Services, Edmonton (T.J.J., A.S., D.G.) and Alberta Health Services, Calgary (C.E.); Department of Medicine (Neurology) (A.Y.X.Y.), University of Toronto, Ontario, Canada; Department of Neurosciences (P.M.C.C.), Monash University, Melbourne, Australia; Department of Clinical Neurosciences (A.M.D., T.J.W., M.D.H., S.B.C.), University of Calgary, Alberta, Canada; Neurology (K.B.), Prince of Wales Clinical School, University of New South Wales, Sydney, Australia., Dean N; From the Department of Medicine (Neurology) (T.J.J., A.S.), and Division of General Internal Medicine (S.R.M., N.D.), University of Alberta (S.F), Edmonton; Alberta Health Services, Edmonton (T.J.J., A.S., D.G.) and Alberta Health Services, Calgary (C.E.); Department of Medicine (Neurology) (A.Y.X.Y.), University of Toronto, Ontario, Canada; Department of Neurosciences (P.M.C.C.), Monash University, Melbourne, Australia; Department of Clinical Neurosciences (A.M.D., T.J.W., M.D.H., S.B.C.), University of Calgary, Alberta, Canada; Neurology (K.B.), Prince of Wales Clinical School, University of New South Wales, Sydney, Australia., Gordon D; From the Department of Medicine (Neurology) (T.J.J., A.S.), and Division of General Internal Medicine (S.R.M., N.D.), University of Alberta (S.F), Edmonton; Alberta Health Services, Edmonton (T.J.J., A.S., D.G.) and Alberta Health Services, Calgary (C.E.); Department of Medicine (Neurology) (A.Y.X.Y.), University of Toronto, Ontario, Canada; Department of Neurosciences (P.M.C.C.), Monash University, Melbourne, Australia; Department of Clinical Neurosciences (A.M.D., T.J.W., M.D.H., S.B.C.), University of Calgary, Alberta, Canada; Neurology (K.B.), Prince of Wales Clinical School, University of New South Wales, Sydney, Australia., Hill MD; From the Department of Medicine (Neurology) (T.J.J., A.S.), and Division of General Internal Medicine (S.R.M., N.D.), University of Alberta (S.F), Edmonton; Alberta Health Services, Edmonton (T.J.J., A.S., D.G.) and Alberta Health Services, Calgary (C.E.); Department of Medicine (Neurology) (A.Y.X.Y.), University of Toronto, Ontario, Canada; Department of Neurosciences (P.M.C.C.), Monash University, Melbourne, Australia; Department of Clinical Neurosciences (A.M.D., T.J.W., M.D.H., S.B.C.), University of Calgary, Alberta, Canada; Neurology (K.B.), Prince of Wales Clinical School, University of New South Wales, Sydney, Australia., Edmond C; From the Department of Medicine (Neurology) (T.J.J., A.S.), and Division of General Internal Medicine (S.R.M., N.D.), University of Alberta (S.F), Edmonton; Alberta Health Services, Edmonton (T.J.J., A.S., D.G.) and Alberta Health Services, Calgary (C.E.); Department of Medicine (Neurology) (A.Y.X.Y.), University of Toronto, Ontario, Canada; Department of Neurosciences (P.M.C.C.), Monash University, Melbourne, Australia; Department of Clinical Neurosciences (A.M.D., T.J.W., M.D.H., S.B.C.), University of Calgary, Alberta, Canada; Neurology (K.B.), Prince of Wales Clinical School, University of New South Wales, Sydney, Australia., Coutts SB; From the Department of Medicine (Neurology) (T.J.J., A.S.), and Division of General Internal Medicine (S.R.M., N.D.), University of Alberta (S.F), Edmonton; Alberta Health Services, Edmonton (T.J.J., A.S., D.G.) and Alberta Health Services, Calgary (C.E.); Department of Medicine (Neurology) (A.Y.X.Y.), University of Toronto, Ontario, Canada; Department of Neurosciences (P.M.C.C.), Monash University, Melbourne, Australia; Department of Clinical Neurosciences (A.M.D., T.J.W., M.D.H., S.B.C.), University of Calgary, Alberta, Canada; Neurology (K.B.), Prince of Wales Clinical School, University of New South Wales, Sydney, Australia.
Jazyk:	angličtina
Zdroj:	Neurology [Neurology] 2023 May 16; Vol. 100 (20), pp. e2093-e2102. Date of Electronic Publication: 2023 Mar 28.
DOI:	10.1212/WNL.0000000000207201
Abstrakt:	Background and Objectives: Urgent transient ischemic attack (TIA) management to reduce stroke recurrence is challenging, particularly in rural and remote areas. In Alberta, Canada, despite an organized stroke system, data from 1999 to 2000 suggested that stroke recurrence after TIA was as high as 9.5% at 90 days. Our objective was to determine whether a multifaceted population-based intervention resulted in a reduction in recurrent stroke after TIA. Methods: In this quasi-experimental health services research intervention study, we implemented a TIA management algorithm across the entire province, centered around a 24-hour physician's TIA hotline and public and health provider education on TIA. From administrative databases, we linked emergency department discharge abstracts to hospital discharge abstracts to identify incident TIAs and recurrent strokes at 90 days across a single payer system with validation of recurrent stroke events. The primary outcome was recurrent stroke; with a secondary composite outcome of recurrent stroke, acute coronary syndrome, and all-cause death. We used an interrupted time series regression analysis of age-adjusted and sex-adjusted stroke recurrence rates after TIA, incorporating a 2-year preimplementation period (2007-2009), a 15-month implementation period, and a 2-year postimplementation period (2010-2012). Logistic regression was used to examine outcomes that did not fit the time series model. Results: We assessed 6,715 patients preimplementation and 6,956 patients postimplementation. The 90-day stroke recurrence rate in the pre-Alberta Stroke Prevention in TIA and mild Strokes (ASPIRE) period was 4.5% compared with 5.3% during the post-ASPIRE period. There was neither a step change (estimate 0.38; p = 0.65) nor slope change (parameter estimate 0.30; p = 0.12) in recurrent stroke rates associated with the ASPIRE intervention implementation period. Adjusted all-cause mortality (odds ratio 0.71, 95% CI 0.56-0.89) was significantly lower after the ASPIRE intervention. Discussion: The ASPIRE TIA triaging and management interventions did not further reduce stroke recurrence in the context of an organized stroke system. The apparent lower mortality postintervention may be related to improved surveillance after events identified as TIAs, but secular trends cannot be excluded. Classification of Evidence: This study provides Class III evidence that a standardized population-wide algorithmic triage system for patients with TIA did not reduce recurrent stroke rate. (© 2023 American Academy of Neurology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu